Astellas Pharma Implements IBM Envizi for ESG Data Management

January 20, 2025, in Tokyo, Japan – Astellas Pharma has revealed a powerful collaboration with IBM Japan to execute the IBM Envizi ESG Suite, which is the most recent technology for managing Environmental, Social and Governance (ESG) metrics. 

The step is in line with Astellas Pharma’s work towards implementing the CSRD and new ESRS standards. This system is planned to come into effect starting October 2025, which should ease the company’s compliance processes regarding 2025 sustainability disclosures.

The month of December 2024 marked the beginning of this implementation, which utilized Accenture Japan’s guidance and IBM Japan’s tech capabilities.

“This partnership guarantees that we remain compliant with sustainability regulations as there is increased need for data transparency,” 

Expressed Hiroshi Matsumoto, Astellas Pharma Senior Manager.

Most companies relegated addressing the need for strong ESG practices to the back burner until the European Commission’s 2023 ESRS guidelines handed them a proverbial wake up call, because now everyone has to step up their game in terms of environmental impact reporting, but this is something Astellas Pharma wishes to tackle head on with the support of IBM Envizi.

 “Empowering companies to meet strong ESG requirements has never been so easy as it is with the Envizi Suite, this is why it is a game changer,” 

Explains Akiko Tanaka, IBM Japan’s Director of ESG Solutions.

Accenture has taken on the job of complete ESG infrastructure development, starting from ideation all the way to implementation of the Envizi platform. Equipped with profound global experience of technical support and operational solutions, IBM Japan now ensures effortless integration to the ever-changing ESG standards. 

With this advanced system, Astellas Pharma plans to enhance the efficiency of their ESG data management, boost transparency, and comply with international regulatory expectations. The company’s partnership with IBM Japan and Accenture Incorporation puts their benchmark for the pharmaceutical industry as a company striving to be a leader in sustainable business practices. 

This partnership accelerates innovation to address the requirements of regulations and corporate responsibility on sustainability issues more broadly.

Read Latest Stories:
Business Needs Samsung’s New Knox Suite

Goldman Sachs’ AI-Driven Strategy to Boost Small Business Growth

iGenius Launches Colosseum 355B to Transform AI for Regulated Sectors

Explore our latest story: Servier and Google Cloud Extend AI Partnership to Accelerate Drug R&D

Servier and Google Cloud Extend AI Partnership to Accelerate Drug R&D